And yes. Patent infringement. Both cases were settled before they went to trial.
They won $18 million against Genzyme in 2004 and $15 million from Applera in 2005. I think those were the biggest.
By the way, they successful won a $15 million settlement back in the day against a big pharma company. I would think that is what they are aiming for against these other big pharmas.
Chances are decent, but after the Supreme Court ruling last year against Myriad, it has been tougher. Obviously the licensing fees they have collected have dropped to almost nothing now. They do have big cases against big pharma, and have won some summary motions, but they have a long ways to go.
Agilent - probably see a trial in late 2015
Glaxosmithkline - probably see a trial in mid 2016
Pfizer, Bristol Myers Squibb, Merial - if they rule to continue, might not see a trial till late 2016.
Natera - rumors they are in settlement talks.
That's what the company hopes will happen, they settle. But these big pharma companies have the resources to keep litigating. GENE is not paying the lawyers unless they win, where they will take a big portion of the settlement. So you would think the lawyers think they might win and will be going for the big settlements. The company is also probably waiting to see what happens before they file new lawsuits. It will be found money if they win, they know the big money is BrevaGenPlus. If they can get to 100,000 tests a year they can get an offer from Myriad.
A prominent scientist has started a big new debate about breast cancer. Geneticist Mary-Claire King of the University of Washington, who identified the first breast cancer gene, is recommending that all women get tested for genetic mutations that can cause breast cancer.
"My colleagues and I are are taking a really bold step," King said. "We're recommending that all adult women in America, regardless of their personal history and regardless of their family history, be offered genetic testing for the breast cancer genes."
But others say that one study is far from enough evidence to know if these women face a higher risk of getting cancer, and that universal testing could lead women to undergo unnecessary surgery, doing more harm than good.
The breast cancer genes are called BRCA1 and BRCA2. Women who have mutations in these genes are much likely to get breast cancer and ovarian cancer. From 5 to 10 percent of breast cancer is caused by BRCA mutations, according to the National Cancer Institute.
Doctors usually recommend women get tested only if one of those cancers runs in their families.
"The difficulty with that approach is that it misses identifying some women who have mutations in these genes," says King, who laid out her arguments in an article published Monday in JAMA, the journal of the American Medical Association. King was awarded a Lasker-Koshland prize Monday for her work on BRCA.
Shots - Health News
Supreme Court Gene Ruling Splits Hairs Over What's 'Natural'
In fact, about half of the women who carry mutations in BRCA1 or BRCA2 have no family history of breast or ovarian cancer, she says.
Shots - Health News
How Being Ignored Helped A Woman Discover The Breast Cancer Gene
But no one has recommended screening all women for a very good reason: No one knew how dangerous the mutations were for the average woman.
"There was a big piece of the puzzle missing," King says.
So King and her colleagues decided to try to find that missing piece. They identified more than 400 women who were carrying the mutations even though they had no family history.
"The women turned out to have the same high risks of developing either breast or ovarian cancer that we see among those who are identified by virtue of their family history," says King, who reported the findings in a paper published last week in the Proceedings of the National Academy of Science.
King thinks that's the tipping point — it's time to recommend all women get screened.
"People who are positive can do something about it. Some women, for instance Angelina Jolie, wrote elegantly about her decision to have a double mastectomy," she says. They could also have their ovaries removed to make sure they never get ovarian cancer.
But that's exactly what has a lot of breast cancer advocates worried.
"We are far, far from being ready to recommend that all women be screened for genetic predisposition to breast cancer," says Fran Visco, president of the National Breast Cancer Coalition.
Visco and others aren't convinced the new data are strong enough to know anything for sure. Just because a woman has one of these mutations doesn't mean she'll definitely get cancer. Thus a woman could undergo radical surgery for no good reason.
"These are very serious surgeries that women have to undergo. Removing their breasts. Removing their ovaries. We're talking about surgery to remove healthy body parts. If we give women this message, we may very well end up doing more harm than good," Visco says.
In addition, screening tests can cost hundreds to thousands of dollars depending on insurance coverage.
"Having the genetic mutation doesn't mean you're definitely going to get cancer," says Dr. Olufunmilayo Olopade, a geneticist at the University of Chicago.
Women who find out they are carrying the mutations could get regular MRIs to try to catch any cancer early, when it's most treatable, Olopade says. They could also do things to try to minimize their chances of getting cancer in the first place. "If you have children, breast-feed children, don't gain weight and eat right — exercise. All those things modify the risk for mutation carriers."
This feels like the last time ROSG went to $20
ATOS ... breast cancer genetic testing. up 8% today. Chart looks breakoutish.
GENE ... breast cancer genetic testing. POS. makes new lows everyday. Just did a restructuring. Releasing new product in two weeks.
RGDX ... pos too. They are slowing increasing revenues.
SQNM... don't really follow it but their message board is hilarious.
Maybe GENE will have it's day? Frustrating to see GENE making new lows everyday and these other genetic companies rallying hard. That's why you diversify. GENE is the dog of my portfolio.
Genomics stocks seeing some momentum? Keep an eye on RGDX and GENE also.
The sector could get interesting. Hopefully the c.c goes well tomorrow for ROSG.
Breast cancer genetic test Brevagen is selling strong, and they are coming out with a new test in a few weeks BrevagenPlus. Could be ready to run with ATOS.
This is what the Deloitte Touche report said about pricing:
The selling price of tests is US$850 but could fall anywhere in the range US$660 to more than $2,000 depending on reimbursement (according to the company’s 2013 Annual Report, the cost of Myriad Genetics’ BRACAnalysisTM in the US is US$3,340, while its 25 gene myRisk Hereditary Cancer panel will have a list price of US$4,000 to $4,500). In using this price, we note that to date the Company has not sought to increase the maximum out of pocket amount a patient is required to pay for the test. We further note one Ohio medical centre that provides BREVAGenTM at no charge in excess of what the patient’s insurer reimburse, generally US$975, and if the insurance company does not pay the full amount, the maximum out of pocket to the patient is US$250 with the same amount charged to patients without insurance.14
$500 is probably their average now because of the insurance rejections. BUT... With clinical trials and perhaps FDA clearance they could then charge around $1500 a test. If you speak with management that is their primary goal is to get insurers on board. Insurers reject it because it is "Investigational, experimental, and unproven." It will be interesting to see how long it will take for the company to get data from those clinical studies.
"Myriad reports BRACAnalysis® testing of around 250,000 per year, predominantly in the US, and if 80% of these were BRCA negative, a target market for BREVAGenTM, then a readily identifiable starting estimate would be 200,000 tests. Almost two million breast biopsies a year might suggest an upper limit to test numbers."
"Revenues of BREVAGenTM are assumed to grow from 6,000 in 2014 at the rate of 100%, 120% (due to broader ethnic suitability and inclusion by US reimbursers as a consequence, and extension to 70 SNPs), 100%, 50%, 25% in 2015, 2016, 2017, 2018 respectively and then declining to record growth of 5% in 2022."
200,000 tests a year = $250,000,000 in revenues a year. The stock would be worth $40-50, but Myriad would probably take them out around the $20 range. That is massive grown for 3-4 years. Especially the way breast cancer genetic testing is taking off, this might be the low end.
From the PR:
"The Company believes that the addressable market of eligible women who meet the appropriate criteria for BREVAGenplus, in the US, is estimated at in excess of 7 million women."
$1200 per test x 7 million women = $9 billion in revenues.
With no competitors in the non-BRCA testing market, they could be the size of Myriad in a few years. The company knows they got to get insurers on board so they can get the $1,200 per test. They are also probably going to move the lab to the U.S to get the medicare/medicaid reimbursements.
Who cares about the other businesses. Heck even the patent lawsuits will pale in comparison if they can sell BrevagenPlus. If they only sell 100,000 a year and get the insurers to reimburse than the stock is worth an easy $40-50 a share. They must be aiming for FDA approval since they are going to be doing clinical trials. Breast cancer genetic testing is also making headlines with big researchers recommending almost all women to get screened.
They are also going to do a Name change, and also Brevagenplus details... They are going to do clinical studies... Sounds as it FDA submittal could be next.
Maybe that is why they are buying up ATOS. Could be pure momo on the breast cancer biotech sector...
And so are the stocks that specialize in it....